0000816956 false 0000816956 2023-07-26 2023-07-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15 (d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

 

Date of Report (Date of earliest event reported): July 26, 2023

 

 

CONMED CORPORATION

(Exact name of registrant as specified in its charter)

 

Delaware 001-39218 16-0977505
(State or other jurisdiction of (Commission File Number) (I.R.S. Employer
incorporation or organization)   Identification No.)

 

 

11311 Concept Blvd

Largo, Florida 33773

(Address of principal executive offices, including zip code)

 

(727) 392-6464

(Registrant's telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (See General Instruction A.2 below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Rule 12(b) of the Act

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $0.01 par value CNMD NYSE

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

Item 2.02 Results of Operations and Financial Condition.

 

On July 26, 2023, CONMED Corporation issued a press release announcing financial results for the second quarter ended June 30, 2023. A copy of this press release is attached hereto as Exhibit 99.1.

 

The information in this Current Report on Form 8-K that is furnished under “Item 2.02. Results of Operations and Financial Condition” and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Act of 1934, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

 

 

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

The following exhibits are included herewith:

 

 

  Exhibit No. Description of Exhibit
     
  99.1 Press Release dated July 26, 2023, issued by CONMED Corporation.
     
  104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

 

Signature

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

     
Date:     July 26, 2023 CONMED CORPORATION
  (Registrant)
     
     
  By: /s/  Todd W. Garner
  Name: Todd W. Garner
  Title: Executive Vice President-
    Chief Financial Officer

 

 

 

 

 

Icon

Description automatically generated

 

NEWS RELEASE
  CONTACT:
  CONMED Corporation
  Todd W. Garner
  Chief Financial Officer
  727-214-2975
  ToddGarner@conmed.com
   

 

 

CONMED Corporation Announces Second Quarter 2023 Financial Results

 

Largo, Florida, July 26, 2023 CONMED Corporation (NYSE: CNMD) today announced financial results for the second quarter ended June 30, 2023.

 

Second Quarter 2023 Highlights

 

·Sales of $317.7 million increased 14.6% year over year as reported and 16.6% in constant currency. Acquisitions contributed approximately 400 basis points of growth.
·Domestic revenue increased 17.1% year over year.
·International revenue increased 11.7% year over year as reported and 16.0% in constant currency.
·Diluted net earnings per share (GAAP) were $0.43 compared to diluted net loss per share (GAAP) of $5.65 in the second quarter of 2022.
·Adjusted diluted net earnings per share(1) were $0.83, an increase of 9.2% compared to the second quarter of 2022.

 

“Our team drove excellent growth across both Orthopedics and General Surgery during the second quarter, building on the momentum we generated during the first three months of the year,” commented Curt R. Hartman, CONMED’s Chair of the Board, President, and Chief Executive Officer. “We remain confident in our ability to grow above market and continue to deliver clinical innovation to our customers.”

 

2023 Outlook

 

Based on the second quarter results, the Company is raising its revenue guidance for the full year 2023 and now expects revenue between $1.230 billion and $1.260 billion, compared to its prior guidance of between $1.205 billion and $1.250 billion.

 

The Company now expects full-year 2023 adjusted diluted net earnings per share(2) in the range of $3.40 to $3.55, compared to its prior range of $3.30 to $3.50.

 

The expected impact of foreign currency exchange rates is unchanged from the Company’s prior guidance.

 

Supplemental Financial Disclosures

 

(1) A reconciliation of reported diluted net earnings (loss) per share to adjusted diluted net earnings per share, a non-GAAP financial measure, appears below.

 

(2) Information reconciling forward-looking adjusted diluted net earnings per share to the comparable GAAP financial measures is unavailable to the company without unreasonable effort, as discussed below.

 

 

 

Conference Call

 

The Company’s management will host a conference call today at 4:30 p.m. ET to discuss its second quarter 2023 results.

 

To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode.  

 

This conference call will also be webcast and can be accessed from the “Investors” section of CONMED's website at www.conmed.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

 

 

 

 

 

 

Consolidated Condensed Statements of Income (Loss)

(in thousands except per share amounts, unaudited)

 

   Three Months Ended  Six Months Ended
   June 30,  June 30,
   2023  2022  2023  2022
             
Net sales  $317,652   $277,190   $613,121   $519,516 
Cost of sales   146,962    125,413    287,110    231,748 
Gross profit   170,690    151,777    326,011    287,768 
% of sales   53.7%    54.8%    53.2%    55.4% 
Selling & administrative expense   129,700    115,826    259,784    218,701 
Research & development expense   13,572    11,493    26,110    22,165 
Income from operations   27,418    24,458    40,117    46,902 
% of sales   8.6%    8.8%    6.5%    9.0% 
Interest expense   9,997    5,928    20,252    10,926 
Other expense       112,011        112,011 
Income (loss) before income taxes   17,421    (93,481)   19,865    (76,035)
Provision for income taxes   3,689    74,810    4,314    77,281 
Net income (loss)  $13,732   $(168,291)  $15,551   $(153,316)
                     
Basic EPS  $0.45   $(5.65)  $0.51   $(5.18)
Diluted EPS   0.43    (5.65)   0.49    (5.18)
                     
Basic shares   30,662    29,775    30,587    29,601 
Diluted shares   31,795    29,775    31,499    29,601 

 

 

 

Sales Summary

(in millions, unaudited)

 

 

   Three Months Ended June 30,
         % Change
                  Domestic  International
   2023  2022  As
Reported
  Impact
of
Foreign
Currency
  Constant
Currency
  As
Reported
  As
Reported
  Impact
of
Foreign
Currency
  Constant
Currency
Orthopedic Surgery  $140.8   $120.2    17.1%    2.7%    19.8%    29.4%    11.0%    3.8%    14.8% 
General Surgery   176.9    157.0    12.6%    1.5%    14.1%    12.5%    12.9%    5.0%    17.9% 
   $317.7   $277.2    14.6%    2.0%    16.6%    17.1%    11.7%    4.3%    16.0% 
                                              
Single-use Products  $264.8   $230.3    14.9%    2.0%    16.9%    15.7%    13.9%    4.5%    18.4% 
Capital Products   52.9    46.9    12.9%    2.2%    15.1%    25.8%    3.4%    3.6%    7.0% 
   $317.7   $277.2    14.6%    2.0%    16.6%    17.1%    11.7%    4.3%    16.0% 
                                              
Domestic  $174.7   $149.2    17.1%    0.0%    17.1%                     
International   143.0    128.0    11.7%    4.3%    16.0%                     
   $317.7   $277.2    14.6%    2.0%    16.6%                     
                                              

 

 
   Six Months Ended June 30,
         % Change
                  Domestic  International
   2023  2022  As
Reported
  Impact
of
Foreign
Currency
  Constant
Currency
  As
Reported
  As
Reported
  Impact
of
Foreign
Currency
  Constant
Currency
Orthopedic Surgery  $272.0   $227.7    19.4%    3.3%    22.7%    29.2%    14.3%    4.9%    19.2% 
General Surgery   341.1    291.8    16.9%    2.0%    18.9%    17.8%    14.9%    6.5%    21.4% 
   $613.1   $519.5    18.0%    2.6%    20.6%    21.0%    14.5%    5.6%    20.1% 
                                              
Single-use Products  $514.0   $431.8    19.0%    2.6%    21.6%    21.8%    15.5%    5.7%    21.2% 
Capital Products   99.1    87.7    13.0%    2.6%    15.6%    15.8%    10.7%    4.8%    15.5% 
   $613.1   $519.5    18.0%    2.6%    20.6%    21.0%    14.5%    5.6%    20.1% 
                                              
Domestic  $339.3   $280.4    21.0%    0.0%    21.0%                     
International   273.8    239.1    14.5%    5.6%    20.1%                     
   $613.1   $519.5    18.0%    2.6%    20.6%                     
                                              

 

 

 

Reconciliation of Reported Net Income (Loss) to Adjusted Net Income

(in thousands, except per share amounts, unaudited)

 

 

 

   Three Months Ended June 30, 2023   
   Gross
Profit
  Selling &
Administrative
Expense
  Operating
Income
  Interest
Expense
  Other
Expense
  Tax
Expense
  Effective
Tax Rate
  Net
Income
  Basic
EPS
  Adjustments  Diluted
EPS
As reported  $170,690   $129,700   $27,418   $9,997   $   $3,689    21.2%   $13,732        $   $ 13,732
% of sales   53.7%    40.8%    8.6%                                    
EPS                                          $0.45        $ 0.43
Shares                                           30,662    1,133   31,795
Acquisition and integration costs(1)   2,173    (303)   2,476            492         1,984              
Termination of distributor agreements(2)       (2,098)   2,098            417         1,681              
Software implementation costs(3)       (1,797)   1,797            357         1,440              
Contingent consideration fair value adjustment(4)       636    (636)           (126)        (510)             
   $172,863   $126,138   $33,153   $9,997   $   $4,829        $18,327              
Adjusted gross profit %   54.4%                                                 
Amortization(5)  $1,500    (7,270)   8,770    (1,506)       2,490         7,786              
As adjusted       $118,868   $41,923   $8,491   $   $7,319    21.9%   $26,113        $   26,113
% of sales        37.4%    13.2%                                            
Adjusted diluted EPS                                                    $ 0.83
                                                           
Shares                                           30,662    1,133   31,795
Convertible note hedges(6)                                                      (214)
Adjusted diluted shares                                                    31,581

 

   Three Months Ended June 30, 2022   
   Gross
Profit
  Selling &
Administrative
Expense
  Operating
Income
  Interest
Expense
  Other
Expense
  Tax
Expense
  Effective
Tax Rate
  Net
Income
(Loss)
  Basic
EPS
   Adjustments(11)  Diluted
EPS
As reported  $151,777   $115,826   $24,458   $5,928   $112,011   $74,810    -80.0%   $(168,291)       $   $ (168,291)
% of sales   54.8%    41.8%    8.8%                                            
EPS                                          $(5.65)       $ (5.65)
Shares                                           29,775       29,775
Acquisition and integration costs(1)   349    (2,600)   2,949            (1,760)        4,709              
Legal matters(7)       (775)   775            (462)        1,237              
Convertible note premium on extinguishment(8)                   (103,125)   (61,521)        164,646              
Change in fair value of convertible note hedges upon settlement(9)                   (5,460)   (3,257)        8,717              
Loss on early extinguishment of debt(10)                   (3,426)   (2,044)        5,470              
   $152,126   $112,451   $28,182   $5,928   $   $5,766        $16,488              
Adjusted gross profit %   54.9%                                                 
Amortization(5)  $1,500    (6,808)   8,308    (1,036)       2,291         7,053              
As adjusted       $105,643   $36,490   $4,892   $   $8,057    25.5%   $23,541        $1,263   $ 24,804
% of sales        38.1%    13.2%                                            
Adjusted diluted EPS                                                    $ 0.76
                                                           
Shares                                           29,775    3,820   33,595
Convertible note hedges(6)                                                      (856)
Adjusted diluted shares                                                    32,739

 

 

 

(1) In 2023, the Company incurred charges related to the amortization of inventory step-up to fair value associated with the acquisition of In2Bones Global, Inc., and integration costs and professional fees associated with the acquisitions of In2Bones Global, Inc. and Biorez, Inc. In 2022, the Company incurred charges related to the amortization of inventory step-up to fair value and consulting and legal related costs associated with the acquisition of In2Bones Global, Inc.

(2) In 2023, the Company incurred costs related to the termination of distributor agreements.

(3) In 2023, the Company incurred additional freight, labor and travel costs as well as professional fees related to the implementation of a warehouse management software.

(4) In 2023, the Company recorded fair value adjustments to contingent consideration.

(5) Includes amortization of intangible assets and deferred financing fees.

(6) Non-GAAP adjusted dilutive weighted average shares outstanding exclude dilution that is expected to be offset by the Company’s convertible notes hedge transactions.

(7) In 2022, the Company incurred costs related to a legal settlement.

(8) In 2022, the Company incurred costs related to the conversion premium on the repurchase and extinguishment of $275.0 million of its 2.625% Convertible Notes.

(9) In 2022, the Company incurred costs related to the settlement of convertible notes hedge transactions associated with the repurchase and extinguishment of $275.0 million of its 2.625% Convertible Notes.

(10) In 2022, the Company incurred costs related to the write-off of deferred financing fees associated with the repurchase and extinguishment of $275.0 million of its 2.625% Convertible Notes and term loan paydown.

(11) The Company adopted ASU 2020-06, effective January 1, 2022. As a result of the adoption, the Company is required to compute diluted EPS using the if-converted method. Under the if-converted method, the numerator is adjusted for interest expense applicable to its convertible notes (net of tax) and the denominator includes additional common shares assuming conversion premium and principal portion of the notes (when permitted or required) are settled in shares. Subsequent to June 6, 2022, the Company is required to settle the principal value of its convertible notes in cash. Adjustments in 2022 are applicable on a non-GAAP basis only since GAAP results are in a loss position and therefore exclude dilutive potential shares.

 

 

 

 

Reconciliation of Reported Net Income (Loss) to Adjusted Net Income

(in thousands, except per share amounts, unaudited)

 

 

 

   Six Months Ended June 30, 2023 
   Gross
Profit
  Selling &
Administrative
Expense
  Operating
Income
  Interest
Expense
  Other
Expense
  Tax
Expense
  Effective
Tax Rate
  Net
Income
  Basic
EPS
  Adjustments  Diluted
EPS
As reported  $326,011   $259,784   $40,117   $20,252   $   $4,314    21.7%   $15,551        $   $ 15,551
% of sales   53.2%    42.4%    6.5%                                        
EPS                                          $0.51        $ 0.49
Shares                                           30,587    912   31,499
Acquisition and integration costs(1)   4,269    (752)   5,021            1,147         3,874              
Termination of distributor agreements(2)       (2,098)   2,098            417         1,681              
Restructuring and related costs(3)   2,035    (1,578)   3,613            930         2,683              
Software implementation costs(4)       (6,056)   6,056            1,453         4,603              
Contingent consideration fair value adjustment(5)       (3,799)   3,799            1,014         2,785              
   $332,315   $245,501   $60,704   $20,252   $   $9,275        $31,177              
Adjusted gross profit %   54.2%                                                 
Amortization(6)  $3,000    (14,535)   17,535    (3,012)       5,020         15,527              
As adjusted       $230,966   $78,239   $17,240   $   $14,295    23.4%   $46,704        $   $ 46,704
% of sales        37.7%    12.8%                                            
Adjusted diluted EPS                                                    $1.49
                                                           
Shares                                           30,587    912   31,499
Convertible note hedges(7)                                                      (138)
Adjusted diluted shares                                                    31,361

 

   Six Months Ended June 30, 2022   
   Gross
Profit
  Selling &
Administrative
Expense
  Operating
Income
  Interest
Expense
  Other
Expense
  Tax
Expense
  Effective
Tax Rate
  Net
Income
(Loss)
  Basic
EPS
   Adjustments(12)  Diluted
EPS
As reported  $287,768   $218,701   $46,902   $10,926   $112,011   $77,281    -101.6%   $(153,316)       $   $ (153,316)
% of sales   55.4%    42.1%    9.0%                                       
EPS                                          $(5.18)       $ (5.18)
Shares                                           29,601       29,601
Acquisition and integration costs(1)   349    (2,600)   2,949            (1,760)        4,709              
Legal matters(8)       (775)   775            (462)        1,237              
Convertible note premium on extinguishment(9)                   (103,125)   (61,521)        164,646              
Change in fair value of convertible note hedges upon settlement(10)                   (5,460)   (3,257)        8,717              
Loss on early extinguishment of debt(11)                   (3,426)   (2,044)        5,470              
   $288,117   $215,326   $50,626   $10,926   $   $8,237        $31,463              
Adjusted gross profit %   55.5%                                                 
Amortization(6)  $3,000    (13,370)   16,370    (1,916)       4,451         13,835              
As adjusted       $201,956   $66,996   $9,010   $   $12,688    21.9%   $45,298        $2,978   $ 48,276
% of sales        38.9%    12.9%                                            
Adjusted diluted EPS                                                    $1.45
                                                           
Shares                                           29,601    4,774   34,375
Convertible note hedges(7)                                                      (1,134)
Adjusted diluted shares                                                    33,241

 

 

 

(1) In 2023, the Company incurred charges related to the amortization of inventory step-up to fair value associated with the acquisition of In2Bones Global, Inc., and integration costs and professional fees associated with the acquisitions of In2Bones Global, Inc. and Biorez, Inc. In 2022, the Company incurred charges related to the amortization of inventory step-up to fair value and consulting and legal related costs associated with the acquisition of In2Bones Global, Inc.

(2) In 2023, the Company incurred costs related to the termination of distributor agreements.

(3) In 2023, the Company incurred consulting fees related to an operational cost improvement initiative and severance related to the elimination of certain positions.

(4) In 2023, the Company incurred additional freight, labor and travel costs as well as professional fees related to the implementation of a warehouse management software.

(5) In 2023, the Company incurred expense related to the fair value adjustments of contingent consideration.

(6) Includes amortization of intangible assets and deferred financing fees.

(7) Non-GAAP adjusted dilutive weighted average shares outstanding exclude dilution that is expected to be offset by the Company’s convertible notes hedge transactions.

(8) In 2022, the Company incurred costs related to a legal settlement.

(9) In 2022, the Company incurred costs related to the conversion premium on the repurchase and extinguishment of $275.0 million of its 2.625% Convertible Notes.

(10) In 2022, the Company incurred costs related to the settlement of convertible notes hedge transactions associated with the repurchase and extinguishment of $275.0 million of its 2.625% Convertible Notes.

(11) In 2022, the Company incurred costs related to the write-off of deferred financing fees associated with the repurchase and extinguishment of $275.0 million of its 2.625% Convertible Notes and term loan paydown.

(12) The Company adopted ASU 2020-06, effective January 1, 2022. As a result of the adoption, the Company is required to compute diluted EPS using the if-converted method. Under the if-converted method, the numerator is adjusted for interest expense applicable to its convertible notes (net of tax) and the denominator includes additional common shares assuming conversion premium and principal portion of the notes (when permitted or required) are settled in shares. Subsequent to June 6, 2022, the Company is required to settle the principal value of its convertible notes in cash. Adjustments in 2022 are applicable on a non-GAAP basis only since GAAP results are in a loss position and therefore exclude dilutive potential shares.

 

 

 

Reconciliation of Reported Net Income (Loss) to EBITDA & Adjusted EBITDA

(in thousands, unaudited) 

 

   Three Months Ended  Six Months Ended
   June 30,  June 30,
   2023  2022  2023  2022
             
Net income (loss)  $13,732   $(168,291)  $15,551   $(153,316)
Provision for income taxes   3,689    74,810    4,314    77,281 
Interest expense   9,997    5,928    20,252    10,926 
Depreciation   4,164    4,059    8,222    8,090 
Amortization   13,900    13,266    27,777    26,065 
EBITDA  $45,482   $(70,228)  $76,116   $(30,954)
                     
Stock based compensation   6,422    5,755    12,148    10,218 
Acquisition and integration costs   2,476    2,949    5,021    2,949 
Termination of distributor agreements   2,098        2,098     
Restructuring and related costs           3,613     
Software implementation costs   1,797        6,056     
Contingent consideration fair value adjustment   (636)       3,799     
Legal matters       775        775 
Convertible notes premium on extinguishment       103,125        103,125 
Change in fair value of convertible notes hedges upon settlement       5,460        5,460 
Loss on early extinguishment of debt       3,426        3,426 
Adjusted EBITDA  $57,639   $51,262   $108,851   $94,999 
                     
                     
EBITDA Margin                    
  EBITDA   14.3%    -25.3%    12.4%    -6.0% 
  Adjusted EBITDA   18.1%    18.5%    17.8%    18.3% 

 

 

About CONMED Corporation

 

CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company’s products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. For more information, visit www.conmed.com.

 

Forward-Looking Statements

 

This press release and associated conference call may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those in the forward-looking statements may include, but are not limited to the risk factors discussed in the Company's Annual Report on Form 10-K for the full year ended December 31, 2022, listed under the heading Forward-Looking Statements in the Company’s most recently filed Form 10-Q and other risks and uncertainties, which may be detailed from time to time in reports filed by CONMED with the SEC. Any and all forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct.

 

Supplemental Information - Reconciliation of GAAP to Non-GAAP Financial Measures

 

The Company supplements the reporting of its financial information determined under generally accepted accounting principles in the United States (GAAP) with certain non-GAAP financial measures, including percentage sales growth in constant currency; adjusted gross profit; cost of sales excluding specified items; adjusted selling and administrative expenses; adjusted operating income; adjusted interest expense; adjusted other expense; adjusted income tax expense; adjusted effective income tax rate; adjusted net income, adjusted diluted shares and adjusted diluted net earnings per share (EPS). The Company believes that these non-GAAP measures provide meaningful information to assist investors and shareholders in understanding its financial results and assessing its prospects for future performance. Management believes percentage sales growth in constant currency and the other adjusted measures described above are important indicators of its operations because they exclude items that may not be indicative of, or are unrelated to, its core operating results and provide a baseline for analyzing trends in the Company’s underlying business. Further, the presentation of EBITDA is a non-GAAP measurement that management considers useful for measuring aspects of the Company’s cash flow. Management uses these non-GAAP financial measures for reviewing the operating results and analyzing potential future business trends in connection with its budget process and bases certain management incentive compensation on these non-GAAP financial measures.

 

Net sales on a constant currency basis is a non-GAAP measure. The Company analyzes net sales on a constant currency basis to better measure the comparability of results between periods. To measure percentage sales growth in constant currency, the Company removes the impact of changes in foreign currency exchange rates that affect the comparability and trend of net sales. To measure earnings performance on a consistent and comparable basis, the Company excludes certain items that affect the comparability of operating results and the trend of earnings. These adjustments are irregular in timing, may not be indicative of past and future performance and are therefore excluded to allow investors to better understand underlying operating trends.

 

 

 

Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures with other companies' non-GAAP financial measures having the same or similar names. These adjusted financial measures should not be considered in isolation or as a substitute for reported sales growth, gross profit, cost of sales, selling and administrative expenses, operating income, interest expense, other expense, income tax expense, effective income tax rate, net income (loss), diluted shares and diluted net earnings (loss) per share, the most directly comparable GAAP financial measures. These non-GAAP financial measures are an additional way of viewing aspects of the Company’s operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures above, provide a more complete understanding of the business. The Company strongly encourages investors and shareholders to review its financial statements and publicly filed reports in their entirety and not to rely on any single financial measure.

 

We are unable to present a quantitative reconciliation of our expected diluted net earnings per share to expected adjusted diluted net earnings per share as we are unable to predict with reasonable certainty and without unreasonable effort the impact and timing of acquisition, integration and other charges. The financial impact of these items is uncertain and is dependent on various factors, including timing, and could be material to our consolidated condensed statements of income.